Regeneron Pharmaceuticals

Regeneron Pharmaceuticals in Fortune Rankings

Regeneron Pharmaceuticals is a major pharmaceutical company that develops and sells drugs covering areas of immunology, oncology, ophthalmology, and rare diseases. During the COVID-19 outbreak it developed a widely used monoclonal antibody treatment. Other flagship products include Eylea, an injection to treat age-related macular degeneration and other eye conditions; Dupixent, a therapy for inflammatory diseases like atopic dermatitis, asthma, and chronic rhinosinusitis; and Libtayo, for certain types of cancer. The company was incorporated in 1988.

Change the World 2026

Regeneron studies the root causes of diseases and identifies new therapies for rare and ultrarare conditions at its genetics center. For example, the company has been studying conditions such as fibrodysplasia ossificans progressiva (FOP), a disabling disease that transforms muscles, ligaments, and other tissue into bone, and is conducting late-stage trials of a FOP treatment. Regeneron is also testing a novel approach to treating lipodystrophy, a rare disorder that leads to low levels of body fat and its abnormal distribution, plus reduced leptin levels, disrupting metabolism.

Updated:9/23/26
Country/Territory:U.S.
Headquarters:Tarrytown, New York
Industry:Pharmaceuticals
CEO:Leonard S. Schleifer
Website:https://www.regeneron.com

Ticker:REGN
Company type:Public
Revenues ($M):$15,535
Profits ($M):$4,329
Market value ($M):$82,269
Number of employees:15,353

Figures are for latest twelve months ended June 30, 2026. Market value as of Aug. 31, 2026.

Rank last year:67
Years on list:7
U.S. employees:9,100
U.S. job openings:600
Year founded:1988

Employees and job openings are U.S.-only.

100% health coverage:No
Unlimited sick days:No
Telecommuting:Yes
Job sharing:No
Subsidized childcare:Confidential
Compressed work weeks:Confidential
Fully-paid sabbaticals:No

On-site fitness/subsidized gym:Yes
On-site medical care facility:No
Non-discrimination policy includes sexual orientation:Yes
Sick days for part-timers:Yes
College tuition reimbursement:Yes
Student loan debt repayment:Yes

# of job applicants:52,430
Avg. # of applicants per opening:33
# New graduates hired:419

Revenue 3 Yr Growth Rank:18
Revenue 3 Yr Annual Growth Rate:49%
EPS 3 Yr Growth Rank:55
EPS 3 Yr Annual Growth Rate:59%
Total Return 3 Yr Rank:55
Total Return 3 Yr Annual Rate:24%
Beat S&P 500 3 Yr Return:no
Current Streak:1
Years on List:4
Sector:Health Care

Overall Score:2.5
Sector:Health Care
Industry:Pharmaceuticals
CEO:Leonard S. Schleifer
Website:https://www.regeneron.com
Employees:5,400
HQ Location:Tarrytown, N.Y.
Revenues ($M) (Past 12 Months):$5,236
Profits ($M) (Past 12 Months):$1,155
Market Value as of Oct. 9, 2019 ($M):$50,054

Industry:Biotechnology & Pharmaceuticals
Industry Vertical:Biotechnology
Founded:1988
City:Tarrytown, N.Y.
Sites:5
Web Address:https://www.regeneron.com
U.S. Employees:8,076
U.S. Revenue:-
Total Worldwide [including U.S.] Revenue in the Latest Fiscal Year:-
Date info provided (companies may opt to keep some data confidential):July 31, 2021

Sector:Health Care
Strongest Dimension:Process innovation
Years on list:1
Previous rank:-
State:New York